Who Paid My Doc
Raymond Dattwyler
Allergy & Immunology Huntington, NY Medical Doctor
NPI 1285658989 CMS profile 12959
325 Park Ave, Huntington, NY 11743
General payments
$7,041
Research payments
$0
Ownership & investment interest
$0
Through program year 2021, Raymond Dattwyler of Huntington, NY is reported in the CMS Open Payments database as having received $7,041 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2021 | General | $7,041 | 5 |
Beside peers
- Raymond Dattwyler
- Allergy & Immunology median
- Middle half of Allergy & Immunology
- National median
In program year 2025, general payments to Raymond Dattwyler were reported at $0. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.
Show as a table
| Year | Raymond Dattwyler | Allergy & Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $378 | $115–$1,178 | $163 |
| 2020 | $0 | $303 | $75–$1,581 | $114 |
| 2021 | $7,041 | $407 | $122–$1,475 | $132 |
| 2022 | $0 | $357 | $120–$1,340 | $149 |
| 2023 | $0 | $445 | $124–$1,536 | $160 |
| 2024 | $0 | $541 | $129–$1,763 | $164 |
| 2025 | $0 | $682 | $143–$2,317 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
13
Drug cost
$46,725
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Dupixent Syringe Dupilumab | Brand | 13 | $46,725 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Allergy & Immunology in New York
Robert Tamayev
Allergy & Immunology · Rego Park, NY
Charlotte Cunningham-Rundles
Allergy & Immunology · New York, NY
Paula Busse
Allergy & Immunology · New York, NY
Mili Shum
Allergy & Immunology · West Harrison, NY
Stanley Schwartz
Allergy & Immunology · Buffalo, NY
Dina Liberman
Allergy & Immunology · Brooklyn, NY
Related records
Allergy & Immunology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Allergy & Immunology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.